Approach to evaluating tumor mutational burden in routine clinical practice

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Immune checkpoint inhibitors offer therapeutic promise but patient response is often unpredictable.
• Predictive biomarkers are essential for selecting patients likely to benefit from these costly treatments.
• Programmed death ligand (PD-L1) expression via immunohistochemistry (IHC) is a limited predictive biomarker due to biological and technical complexities.

Purpose of the Study:

• To review current approaches for measuring tumor mutational burden (TMB).
• To highlight ongoing efforts in harmonizing TMB as a predictive biomarker for immunotherapy.
• To underscore the need for standardized biomarker assessment in cancer treatment.

Main Methods:

• Review of existing literature on TMB measurement techniques.
• Discussion of standardization initiatives for TMB assessment.
• Analysis of TMB's role as a predictive biomarker in immunotherapy.

Main Results:

• Tumor mutational burden (TMB) shows promise as a predictive biomarker for immunotherapy efficacy across various tumor types.
• TMB is expected to be integrated into future treatment algorithms for immune checkpoint inhibitors.
• Standardization of TMB measurement is critical for consistent and reliable clinical application.

Conclusions:

• Harmonizing TMB measurement is essential for accurate prediction of immunotherapy response.
• Standardized TMB assessment will facilitate meaningful comparisons of treatment efficacy.
• Further efforts are needed to refine and standardize TMB as a key biomarker in clinical oncology.